UNIONDALE, NY, USA I June 22, 2017 I Angion Biomedica Corp. announced today that it has signed an exclusive license with ElexoPharm GmbH of Saarbrücken, Germany, for compounds that target aldosterone synthase (CYP11B2), a cytochrome P450 enzyme involved in the generation of aldosterone. Reducing aldosterone levels may be an effective approach to treating chronic kidney disease, heart failure, hypertension and fibrosis. The exclusive license agreement complements Angion’s ongoing R&D program for this target pursuant to an NIDDK/NIH grant. “The novel ElexoPharm portfolio of compounds provides for a valuable source of new chemical entities in order to help Angion advance its programs in chronic kidney disease (CKD)”, said Itzhak D. Goldberg, M.D., Angion’s CEO.
ElexoPharm was founded in 2005 as a spin-off of the Saarland University in Germany. ElexoPharm obtained its aldosterone synthase inhibitors from the lab of Professor Rolf Hartmann, a world-renowned expert in this field. Dr. Hartmann’s team identified novel classes of highly selective aldosterone synthase inhibitors (CYP11B2) that spare the closely related CYP11B1 target. “We are greatly pleased to have a close relationship with Angion in order to facilitate the advancement of potent compounds into the clinic for the treatment of CKD. Chronic renal disease affects an enormous patient population, a condition for which there is currently no effective treatment.” said Professor Hartmann.
“This license agreement and promising collaboration with Dr. Hartmann’s outstanding team is consistent with Angion’s mission to develop new therapeutics to address the full spectrum of renal diseases, which is estimated to affect one in ten Americans” said Dr. Goldberg.
About Angion Biomedica Corp.
Angion Biomedica Corp. is a biopharmaceutical company established in 1998 to discover and develop novel therapeutic agents to treat patients who experience acute and chronic organ disorders and diseases. Angion is currently conducting clinical studies in renal transplantation and acute kidney injury utilizing its proprietary therapeutic BB3 and has additional preclinical programs for chronic renal diseases. For further information, please visit www.angion.com, or contact us at mail@angion.com.
SOURCE: Angion Biomedica
Post Views: 30
UNIONDALE, NY, USA I June 22, 2017 I Angion Biomedica Corp. announced today that it has signed an exclusive license with ElexoPharm GmbH of Saarbrücken, Germany, for compounds that target aldosterone synthase (CYP11B2), a cytochrome P450 enzyme involved in the generation of aldosterone. Reducing aldosterone levels may be an effective approach to treating chronic kidney disease, heart failure, hypertension and fibrosis. The exclusive license agreement complements Angion’s ongoing R&D program for this target pursuant to an NIDDK/NIH grant. “The novel ElexoPharm portfolio of compounds provides for a valuable source of new chemical entities in order to help Angion advance its programs in chronic kidney disease (CKD)”, said Itzhak D. Goldberg, M.D., Angion’s CEO.
ElexoPharm was founded in 2005 as a spin-off of the Saarland University in Germany. ElexoPharm obtained its aldosterone synthase inhibitors from the lab of Professor Rolf Hartmann, a world-renowned expert in this field. Dr. Hartmann’s team identified novel classes of highly selective aldosterone synthase inhibitors (CYP11B2) that spare the closely related CYP11B1 target. “We are greatly pleased to have a close relationship with Angion in order to facilitate the advancement of potent compounds into the clinic for the treatment of CKD. Chronic renal disease affects an enormous patient population, a condition for which there is currently no effective treatment.” said Professor Hartmann.
“This license agreement and promising collaboration with Dr. Hartmann’s outstanding team is consistent with Angion’s mission to develop new therapeutics to address the full spectrum of renal diseases, which is estimated to affect one in ten Americans” said Dr. Goldberg.
About Angion Biomedica Corp.
Angion Biomedica Corp. is a biopharmaceutical company established in 1998 to discover and develop novel therapeutic agents to treat patients who experience acute and chronic organ disorders and diseases. Angion is currently conducting clinical studies in renal transplantation and acute kidney injury utilizing its proprietary therapeutic BB3 and has additional preclinical programs for chronic renal diseases. For further information, please visit www.angion.com, or contact us at mail@angion.com.
SOURCE: Angion Biomedica
Post Views: 30
